Published Date: 20-11-2018
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report North America Contrast Injector Systems Market, published by KBV research, the North America Contrast Injector Systems Market would witness market growth of 7.0% CAGR during the forecast period (2018 – 2024).
The USA market would dominate the North America Injector Systems Market by 2024; growing at a CAGR of 6.9 % during the forecast period. The Canada market is expected to witness a CAGR of 7.7% during (2018 - 2024). Additionally, The Mexico market is expected to witness a CAGR of 9.8% during (2018 - 2024).
The Hospitals market dominated the North America Contrast Injector Systems Market by End User in 2017. The Diagnostics Centers market is expected to witness a CAGR of 6.3% during (2018 - 2024).
The Radiology market dominated the Mexico Contrast Injector Systems Market by Application in 2017, thereby, achieving a market value of $16.3 million by 2024. The Interventional Radiology market is expected to witness a CAGR of 9.2% during (2018 - 2024). Additionally, The Interventional Cardiology market is expected to witness highest CAGR of 11.1% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer Ag, Angiodynamics Inc., GE Healthcare (A Healthcare Division of GE Company), Medtron AG, Nemoto Kyorindo Co., Ltd., Sino Medical- Device Technology Co., Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., Ulrich GmbH & Co. Kg, Vivid Imaging and Guerbet Group.
By End User
Unique Offerings from KBV Research